- Home
- VCNX vs PETZ Comparison
VCNX vs PETZ Comparison
Compare VCNX & PETZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VCNX
- PETZ
- Stock Information
- Founded
- VCNX 2001
- PETZ 2002
- Country
- VCNX United States
- PETZ China
- Employees
- VCNX N/A
- PETZ N/A
- Industry
- VCNX Biotechnology: Pharmaceutical Preparations
- PETZ Steel/Iron Ore
- Sector
- VCNX Health Care
- PETZ Industrials
- Exchange
- VCNX Nasdaq
- PETZ Nasdaq
- Market Cap
- VCNX 10.5M
- PETZ 12.2M
- IPO Year
- VCNX N/A
- PETZ 2017
- Fundamental
- Price
- VCNX $1.41
- PETZ $1.15
- Analyst Decision
- VCNX
- PETZ
- Analyst Count
- VCNX 0
- PETZ 0
- Target Price
- VCNX N/A
- PETZ N/A
- AVG Volume (30 Days)
- VCNX 96.1K
- PETZ 15.6K
- Earning Date
- VCNX 11-14-2024
- PETZ 12-17-2024
- Dividend Yield
- VCNX N/A
- PETZ N/A
- EPS Growth
- VCNX N/A
- PETZ N/A
- EPS
- VCNX N/A
- PETZ N/A
- Revenue
- VCNX $388,000.00
- PETZ $3,278,453.00
- Revenue This Year
- VCNX N/A
- PETZ N/A
- Revenue Next Year
- VCNX N/A
- PETZ N/A
- P/E Ratio
- VCNX N/A
- PETZ N/A
- Revenue Growth
- VCNX N/A
- PETZ 2.46
- 52 Week Low
- VCNX $1.25
- PETZ $0.96
- 52 Week High
- VCNX $13.02
- PETZ $1.74
- Technical
- Relative Strength Index (RSI)
- VCNX 27.23
- PETZ 45.08
- Support Level
- VCNX $3.34
- PETZ $1.10
- Resistance Level
- VCNX $4.35
- PETZ $1.26
- Average True Range (ATR)
- VCNX 0.50
- PETZ 0.07
- MACD
- VCNX -0.19
- PETZ -0.00
- Stochastic Oscillator
- VCNX 4.87
- PETZ 31.25
About VCNX Vaccinex Inc.
Vaccinex Inc is pioneering a differentiated approach to treating cancer and slowly progressive neurodegenerative diseases through the inhibition of semaphorin 4D (SEMA4D). The company's lead drug candidate, pepinemab, blocks SEMA4D, a potent biological effector that it believes prevents immune infiltration into tumors and triggers inflammation in chronic diseases of the brain. Pepinemab is being evaluated in a Phase 1b/2 study in recurrent or metastatic head and neck cancer and in a Phase 1/2a study in Alzheimer's Disease, with ongoing exploration of potential Phase 3 development in Huntington's disease. The firm has also developed a proprietary drug discovery platform, ActivMAb.
About PETZ TDH Holdings Inc.
TDH Holdings Inc is engaged in the business of manufacturing and selling of petfood and restaurant operations. The company has two operating segments which include Petfood sales and Restaurant business. It has a focus on the Restaurant business segment and generates the majority of its revenue.